Alle Fälle anzeigen
UPC APP 44530/2024
—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieSonstige prozessuale
- Parteien
- Beklagte
- Amgen Technology (Ireland) Unlimited Company
- Amgen N.V.
- Amgen GmbH (Germany)
- Amgen GmbH (Austria)
- Amgen AB
- Amgen S.A.S.
- Amgen s.r.l.
- Amgen Biofarmacêutica Lda.
- Amgen Zdravila D.O.O.
Vertreter: Tilman Müller-Stoy (Bardehle Pagenberg) - Division
- Court of Appeal
- Richter
- Klaus Grabinski · President of the Court of Appeal and judge-rapporteur
- Technology
- Organic Chemistry
- Sprache
- —
- Erste Entscheidung
- 8. Aug. 2024
Entscheidungen
- 2024-08-08Generic application
The Court of Appeal ruled that service of written pleadings must be effected through the Court's electronic CMS and that prior communication via Germany's beA (besonderes elektronisches Anwaltspostfach) does not constitute effective service under R.278.1 RoP.
Rechtsfragen:Service of documentsR.278.1 RoPElectronic CMS servicebeA (besonderes elektronisches Anwaltspostfach)
Dokumente
- 1866B3ED297FAF985BD82B5945677424_en.pdf2024-08-08EN